QurAlis
Dr. Daniel Elbaum is a drug discovery and development leader with more than 21 years of experience. He thrives on making new discoveries and connections, and has made significant contributions in the fields of oncology, inflammation, and orphan diseases. He has worked in both large (Pfizer and Amgen) organizations as well as several start-up companies including Kinetix, and FoldRx. He was Senior Director, Chemistry & Portfolio Management and co-head of the Research and Non-clinical Development group at Retrophin. To keep abreast of cutting-edge research, he actively maintains close ties with the academic and start-up communities.
Dan‘s undergraduate and Ph.D. degrees in Chemistry are from Harvard University, and he conducted post-doctoral research at the University of Pennsylvania. An inventor on more than 25 patents and an author on more than 15 peer-reviewed publications, he is a mentor in the Kindle Mentors Program at Boston University and a longstanding member of the American Chemical Society and the Association for the Advancement of Science.
This person is not in any offices
QurAlis
1 followers
QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. They are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus their programs on tackling specific disease-causing mechanisms.